Today, the U.S. Food and Drug Administration (FDA) approved
Yupelri (revefenacin) Inhalation Solution for the maintenance treatment
of patients with chronic obstructive pulmonary disease (COPD).
Revefenacin is a long-acting muscarinic antagonist (LAMA), which is a
class of medicines that improve lung function in patients with COPD.
Revefenacin is an inhalation solution that is administered once daily via
a standard jet nebulizer.
As with other inhaled medicines, revefenacin can cause paradoxical
bronchospasm (wheezing). If paradoxical bronchospasm occurs, patients
should discontinue use. Patients should also be alert for signs and
symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort,
blurred vision, visual changes). Patients should consult a healthcare
professional immediately if any of these signs or symptoms develop.
The most common adverse reactions include cough, nasopharyngitis
(swelling of the nasal passages and the back of the throat), upper
respiratory tract infection, headache, and back pain. Health care
professionals should avoid administering revefenacin with other
anticholinergic-containing drugs. The agency does not recommend
administering revefenacin at the same time as OATP1B1 and OATP1B3
inhibitors (e.g. rifampicin, cyclosporine, etc.), as it may lead to an
increase in exposure of the active metabolite.
.png)
No hay comentarios:
Publicar un comentario